PR Newswire Clinical TrialsOriginal article
Senhwa Completes Enrollment in Phase 1b CX-5461 Expansion Trial; CSR Expected in Q1 2027
Phase 1pidnarulexPositive
AI Analysis
Summary
Senhwa Biosciences announced completion of enrollment in its Phase 1b expansion trial of pidnarulex (CX-5461) for advanced solid tumors with homologous recombination deficiency, with clinical study report expected in Q1 2027.
Clinical Trial Data
Phase
1b
Outcome Details
Phase 1b expansion trial enrollment completed
Importance:5/10
Sentiment:
0.60
clinical trialenrollment completiononcologyPhase 1bDNA repair
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 25, 2026 6:56 AM